Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients

Abstract Background Stroke is a leading cause of death and disability. Trials suggest that sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-receptor-1 receptor agonists (GLP-1 RAs) reduce cardiovascular risk in selected populations. Objectives To describe facility-level...

Полное описание

Библиографические подробности

Главные авторы:	Qinglan Ding, Jason J. Sico, Anthony J. Perkins, Laura J. Myers, Joanne K. Daggy, Ali Sexson, Stanley E. Taylor, Laura Burrone, Kimberly Waddell, Dawn M. Bravata
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BioMed Central 2026-03-01
Серии:	Cardiovascular Diabetology. Endocrinology Reports
Предметы:	Glucagon-like peptide-1 receptor agonists Type 2 diabetes Sodium glucose cotransporter-2 inhibitors Ischemic stroke Prescribing patterns Veterans
Online-ссылка:	https://doi.org/10.1186/s40842-026-00280-w
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!